FDA Using More Temporary Advisory Committee Members To Fill Vacancies
FDA advisory committees are increasingly relying on temporary members to fill their ranks - a trend that could result in less predictability for drug sponsors at a make-or-break review meeting
More from Archive
More from Pink Sheet
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.